Sangamo showcases progress in our pre-clinical programs at ASGCT.

Click here to view

Uncategorized

Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
September 20th, 2023
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
August 8th, 2023
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
August 1st, 2023
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
July 20th, 2023
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
July 17th, 2023
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
June 29th, 2023
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
May 22nd, 2023
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
May 16th, 2023
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 2nd, 2023
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
April 26th, 2023